Clinical trials: Hypertension (HTN)
Pulmonary Arterial Hypertension
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
- Trial name
- BREEZE (NCT03950739)
- Testing
- Treprostinil Inhalation Powder
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
A Mobile Health Intervention in Pulmonary Arterial Hypertension
This study proposes the use of a mobile health intervention (utilizing a smart phone app) to encourage increased exercise in PAH patients.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
- Trial name
- mHealth (NCT03069716)
- Testing
- Smartphone Text Messaging, Fitbit Charge HR
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Vanderbilt University Medical Center
Liver Cirrhosis
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and…
- Trial name
- ZEAL (NCT05516498)
- Testing
- Part A: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin
- Where
- 50 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Hyperlipidemia, Diabetes
Tele-Pharmacy Intervention to Improve Treatment Adherence
The purpose of this cluster randomized controlled trial is to evaluate whether a novel tele-pharmacist-based intervention for patients with hyperlipidemia, hypertension, and diabetes improves medication adherence, disease…
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- STIC2IT (NCT02512276)
- Testing
- Telepharmacist intervention
- Where
- United States
- Volunteers
- 4,078 people
- Sponsor
- Brigham and Women's Hospital
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cardiovascular Diseases, Heart Diseases
Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension
The purpose of this study is to reduce adverse self-medication practices in older adults with hypertension.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypertension
- Trial name
- NCT00201201
- Testing
- Education Intervention, Control
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Connecticut
Ocular Hypertension, Glaucoma
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma.
- Trial name
- NCT01033422
- Testing
- CF101
- Where
- 3 sites in Bulgaria, Israel
- Volunteers
- 89 people
- Sponsor
- Can-Fite BioPharma
Glaucoma
Screening and Intervention for Glaucoma and Eye Health Through Telemedicine
This is a multiple site, randomized study that will assess the effects of personalized eHealth education and motivational-interviewing-based counseling on patient adherence to physician follow-up appointments.
- Trial name
- SIGHT (NCT04274764)
- Testing
- Personalized eHealth Education & Motivational Interviewing
- Where
- 2 sites in United States
- Volunteers
- 622 people
- Sponsor
- University of Michigan
Severe Pulmonary Arterial Hypertension
Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.
- Trial name
- NCT02042014
- Testing
- QTI571
- Where
- 3 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients
The purpose of this study is to determine the safety, tolerability and efficacy of Amlodipine and Olmesartan medoxomil among Hypertensive Filipino patients.
- Trial name
- NCT01200407
- Testing
- Amlodipine + Olmesartan medoxomil
- Where
- 51 sites in Philippines
- Volunteers
- 615 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Effects of Oral Sildenafil on Mortality in Adults With PAH
This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]).
- Trial name
- AFFILIATE (NCT02060487)
- Testing
- sildenafil citrate
- Where
- 82 sites in United States, Australia and 21 more
- Volunteers
- 385 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Moderate to Severe Hypertension
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis…
- Trial name
- NCT00841672
- Testing
- Aliskiren/amlodipine 300/10 mg tablet, Amlodipine 10 mg capsule
- Where
- 6 sites in Germany, Philippines and 4 more
- Volunteers
- 485 people
- Sponsor
- Novartis
Hypertension
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses.
- Trial name
- NCT01150357
- Testing
- Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients.
- Trial name
- NCT00934089
- Testing
- PF-04217329, latanoprost vehicle, latanoprost
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623).
- Trial name
- PERFECT OLE (NCT03794583)
- Testing
- Inhaled treprostinil solution
- Where
- 32 sites in United States, Israel and 1 more
- Volunteers
- 41 people
- Sponsor
- United Therapeutics
Hernia, Diaphragmatic, Hypertension, Pulmonary
Chronic Sildenafil for Severe Diaphragmatic Hernia
The purpose of this study is to test if sildenafil is effective in the treatment of infants with severe congenital diaphragmatic hernia (determined by the presence of prolonged pulmonary hypertension or prolonged oxygen…
- Conditions
- Hernia, Diaphragmatic, Hypertension, Pulmonary, Hypoplasia, Pulmonary
- Trial name
- NCT00133679
- Testing
- sildenafil
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Francisco
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma
Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes
This clinical trial compares two implantable devices intended to lower the pressure inside the eye of glaucoma patients.
- Conditions
- Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
- Trial name
- COMPARE (NCT02023242)
- Testing
- Hydrus Microstent, iStent Trabecular Micro Bypass
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Ivantis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.